Display options
Cite
Burocchi A, Colombo MP, Piconese S. Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol. 2013;4:247doi: 10.3389/fimmu.2013.00247.
Burocchi, A., Colombo, M. P., & Piconese, S. (2013). Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Frontiers in immunology, 4247. https://doi.org/10.3389/fimmu.2013.00247
Burocchi, Alessia, et al. "Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer." Frontiers in immunology vol. 4 (2013): 247. doi: https://doi.org/10.3389/fimmu.2013.00247
Burocchi A, Colombo MP, Piconese S. Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol. 2013 Aug 27;4:247. doi: 10.3389/fimmu.2013.00247. eCollection 2013. PMID: 23986759; PMCID: PMC3753661.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2013 Aug 27;4:247. doi: 10.3389/fimmu.2013.00247. eCollection 2013.

Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer.

Frontiers in immunology

Alessia Burocchi, Mario P Colombo, Silvia Piconese

Affiliations

  1. Molecular Immunology Unit, Department of Experimental Medicine, Fondazione IRCCS "Istituto Nazionale Tumori," Milan , Italy.

PMID: 23986759 PMCID: PMC3753661 DOI: 10.3389/fimmu.2013.00247

Abstract

The expansion of regulatory T cells (Treg) is a common event characterizing the vast majority of human and experimental tumors and it is now well established that Treg represent a crucial hurdle for a successful immunotherapy. Treg are currently classified, according to their origin, into thymus-derived Treg (tTreg) or peripherally induced Treg (pTreg) cells. Controversy exists over the prevalent mechanism accounting for Treg expansion in tumors, since both tTreg proliferation and de novo pTreg differentiation may occur. Since tTreg and pTreg are believed as preferentially self-specific or broadly directed to non-self and tumor-specific antigens, respectively, the balance between tTreg and pTreg accumulation may impact on the repertoire of antigen specificities recognized by Treg in tumors. The prevalence of tTreg or pTreg may also affect the outcome of immunotherapies based on tumor-antigen vaccination or Treg depletion. The mechanisms dictating pTreg induction or tTreg expansion/stability are a matter of intense investigation and the most recent results depict a complex landscape. Indeed, selected Treg subsets may display peculiar characteristics in terms of stability, suppressive function, and cytokine production, depending on microenvironmental signals. These features may be differentially distributed between pTreg and tTreg and may significantly affect the possibility of manipulating Treg in cancer therapy. We propose here that innovative immunotherapeutic strategies may be directed at diverting unstable/uncommitted Treg, mostly enriched in the pTreg pool, into tumor-specific effectors, while preserving systemic immune tolerance ensured by self-specific tTreg.

Keywords: Treg development; epigenetic commitment; heterogeneity; plasticity; specialization; tumor antigens

References

  1. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54 - PubMed
  2. Nat Immunol. 2009 Jul;10(7):689-95 - PubMed
  3. Blood. 2006 Jan 15;107(2):628-36 - PubMed
  4. Mol Immunol. 2010 Apr;47(7-8):1595-600 - PubMed
  5. Immunity. 2009 Nov 20;31(5):772-86 - PubMed
  6. Immunity. 2008 Apr;28(4):546-58 - PubMed
  7. J Exp Med. 2011 Sep 26;208(10):2055-67 - PubMed
  8. J Exp Med. 2012 Sep 24;209(10):1713-22, S1-19 - PubMed
  9. Annu Rev Immunol. 2012;30:531-64 - PubMed
  10. Clin Cancer Res. 2008 Jan 1;14(1):178-87 - PubMed
  11. Cancer Immun. 2007 Mar 28;7:7 - PubMed
  12. Sci Transl Med. 2012 Dec 12;4(164):164ra159 - PubMed
  13. Semin Cancer Biol. 2012 Feb;22(1):23-32 - PubMed
  14. Eur J Immunol. 2012 Jul;42(7):1876-85 - PubMed
  15. Clin Cancer Res. 2009 Oct 15;15(20):6348-57 - PubMed
  16. Blood. 2007 Apr 1;109(7):2871-7 - PubMed
  17. Annu Rev Immunol. 2012;30:733-58 - PubMed
  18. Nat Immunol. 2005 Dec;6(12):1219-27 - PubMed
  19. Blood. 2007 Aug 15;110(4):1225-32 - PubMed
  20. J Immunol. 2009 Apr 15;182(8):4675-85 - PubMed
  21. J Exp Med. 2010 Jul 5;207(7):1393-407 - PubMed
  22. Nat Immunol. 2009 Sep;10(9):1000-7 - PubMed
  23. Neuro Oncol. 2011 Dec;13(12):1308-23 - PubMed
  24. Science. 2003 Feb 14;299(5609):1057-61 - PubMed
  25. J Clin Oncol. 2009 Jan 10;27(2):186-92 - PubMed
  26. Gastroenterology. 2009 Oct;137(4):1270-9 - PubMed
  27. Nature. 2009 Mar 19;458(7236):351-6 - PubMed
  28. J Exp Med. 2007 Jun 11;204(6):1257-65 - PubMed
  29. J Clin Invest. 2009 Nov;119(11):3311-21 - PubMed
  30. Nat Rev Immunol. 2012 Feb 10;12(3):157-67 - PubMed
  31. Cancer Res. 2011 Feb 1;71(3):736-46 - PubMed
  32. J Exp Med. 2007 Jul 9;204(7):1543-51 - PubMed
  33. Nat Genet. 2001 Jan;27(1):20-1 - PubMed
  34. Nat Med. 2004 Sep;10(9):909-15 - PubMed
  35. Eur J Immunol. 2013 Jun;43(6):1518-28 - PubMed
  36. Clin Cancer Res. 2007 Nov 1;13(21):6301-11 - PubMed
  37. Mol Med. 2013 Feb 08;18:1499-508 - PubMed
  38. Nature. 2012 Feb 08;482(7385):395-9 - PubMed
  39. Blood. 2012 Jun 14;119(24):5688-96 - PubMed
  40. J Immunol. 1999 Nov 15;163(10):5211-8 - PubMed
  41. Immunity. 2007 Oct;27(4):635-46 - PubMed
  42. J Immunol. 2012 Dec 15;189(12):5638-48 - PubMed
  43. PLoS One. 2012;7(10):e47190 - PubMed
  44. Cancer Res. 2009 Jan 15;69(2):599-608 - PubMed
  45. Eur J Immunol. 2011 Dec;41(12):3564-73 - PubMed
  46. J Exp Med. 2005 Oct 3;202(7):885-91 - PubMed
  47. Immunity. 2011 Apr 22;34(4):566-78 - PubMed
  48. Immunity. 2009 May;30(5):626-35 - PubMed
  49. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12087-92 - PubMed
  50. Gut. 2009 Apr;58(4):520-9 - PubMed
  51. J Immunol. 2007 Apr 1;178(7):4051-61 - PubMed
  52. Immunity. 2008 Jul 18;29(1):114-26 - PubMed
  53. PLoS One. 2012;7(10):e48424 - PubMed
  54. Oncoimmunology. 2012 Aug 1;1(5):642-648 - PubMed
  55. Science. 2009 Nov 13;326(5955):986-91 - PubMed
  56. PLoS One. 2012;7(3):e34547 - PubMed
  57. Eur J Immunol. 2008 Jun;38(6):1654-63 - PubMed
  58. Nature. 2011 Feb 24;470(7335):548-53 - PubMed
  59. Nat Med. 2011 Jul 24;17(8):983-8 - PubMed
  60. Immunity. 2004 Oct;21(4):503-13 - PubMed
  61. Cancer Res. 2006 Jul 15;66(14):7301-9 - PubMed
  62. J Immunol. 2013 Feb 1;190(3):1076-84 - PubMed
  63. Cancer Res. 2001 Jun 15;61(12):4766-72 - PubMed
  64. Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5919-24 - PubMed
  65. PLoS One. 2006 Dec 27;1:e129 - PubMed
  66. J Immunol. 2007 Mar 1;178(5):2883-92 - PubMed
  67. Science. 1993 Feb 12;259(5097):974-7 - PubMed
  68. J Clin Invest. 2007 Sep;117(9):2570-82 - PubMed
  69. Nat Immunol. 2003 Apr;4(4):330-6 - PubMed
  70. Science. 2013 Mar 8;339(6124):1219-24 - PubMed
  71. Nature. 2010 Feb 11;463(7282):808-12 - PubMed
  72. J Immunol. 2010 Jun 1;184(11):6545-51 - PubMed
  73. Nat Rev Cancer. 2007 Nov;7(11):880-7 - PubMed
  74. Cell Immunol. 2012 Jul-Aug;278(1-2):76-83 - PubMed
  75. Immunity. 2004 Jan;20(1):107-18 - PubMed
  76. J Exp Med. 2005 Oct 3;202(7):919-29 - PubMed
  77. Clin Cancer Res. 2006 Jan 15;12(2):465-72 - PubMed
  78. Blood. 2012 Mar 22;119(12):2810-8 - PubMed
  79. Immunity. 2012 Nov 16;37(5):785-99 - PubMed
  80. PLoS Biol. 2007 Feb;5(2):e38 - PubMed
  81. J Clin Invest. 2009 Sep;119(9):2648-62 - PubMed
  82. Science. 2008 Oct 10;322(5899):271-5 - PubMed
  83. Nat Genet. 2001 Jan;27(1):68-73 - PubMed
  84. PLoS One. 2013;8(2):e56209 - PubMed
  85. PLoS One. 2011;6(7):e22845 - PubMed
  86. Nature. 2011 Jul 13;475(7355):226-30 - PubMed
  87. Exp Dermatol. 2010 Aug;19(8):e213-21 - PubMed
  88. J Immunol. 2011 Apr 1;186(7):4388-95 - PubMed
  89. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5238-42 - PubMed
  90. Epigenetics. 2011 Feb;6(2):236-46 - PubMed
  91. Int J Cancer. 2010 Jun 1;126(11):2635-43 - PubMed
  92. Cancer Immunol Immunother. 2013 May;62(5):897-908 - PubMed
  93. Curr Opin Immunol. 2009 Jun;21(3):281-5 - PubMed
  94. Science. 2010 Sep 24;329(5999):1667-71 - PubMed
  95. Immunity. 2008 Mar;28(3):402-13 - PubMed
  96. J Immunol. 2009 Mar 15;182(6):3461-8 - PubMed
  97. J Immunol. 2012 Feb 1;188(3):976-80 - PubMed
  98. Eur J Immunol. 2011 Dec;41(12):3615-26 - PubMed
  99. Clin Immunol. 2011 Sep;140(3):218-22 - PubMed
  100. Nat Genet. 2001 Jan;27(1):18-20 - PubMed
  101. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20884-9 - PubMed
  102. PLoS One. 2012;7(10):e46600 - PubMed
  103. Nat Immunol. 2013 Apr;14(4):307-8 - PubMed
  104. J Immunol. 2011 Jun 15;186(12):6779-87 - PubMed
  105. Nat Immunol. 2009 Jun;10(6):595-602 - PubMed
  106. Gastroenterology. 2011 Mar;140(3):957-65 - PubMed
  107. Clin Cancer Res. 2011 Feb 15;17(4):841-8 - PubMed
  108. J Immunol. 2008 May 15;180(10):6467-71 - PubMed
  109. Nat Med. 2011 Jun;17(6):673-5 - PubMed
  110. Semin Cancer Biol. 2012 Aug;22(4):327-34 - PubMed
  111. J Immunol. 2005 Mar 1;174(5):2661-70 - PubMed
  112. PLoS One. 2013;8(1):e53630 - PubMed
  113. Immunity. 2012 Sep 21;37(3):501-10 - PubMed
  114. Immunity. 2010 Dec 14;33(6):942-54 - PubMed
  115. J Exp Med. 2012 Sep 24;209(10):1723-42, S1 - PubMed
  116. Cancer Res. 2009 May 1;69(9):3995-4000 - PubMed
  117. Blood. 2013 Feb 21;121(8):1265-75 - PubMed
  118. Immunity. 2011 Jul 22;35(1):109-22 - PubMed
  119. Cancer Immunol Immunother. 2009 Sep;58(9):1363-73 - PubMed
  120. Immunity. 2004 Oct;21(4):589-601 - PubMed
  121. Oncoimmunology. 2012 Mar 1;1(2):152-161 - PubMed
  122. Cancer Res. 2006 Apr 15;66(8):4488-95 - PubMed
  123. Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10902-6 - PubMed
  124. Immunity. 2012 Feb 24;36(2):262-75 - PubMed
  125. J Immunol. 2004 May 1;172(9):5213-21 - PubMed
  126. Cancer Res. 2005 Feb 15;65(4):1577-86 - PubMed
  127. Blood. 2006 May 15;107(10):3940-9 - PubMed
  128. J Immunol. 2012 Sep 15;189(6):2890-6 - PubMed
  129. Cancer Res. 2012 Sep 1;72(17):4351-60 - PubMed
  130. Nat Rev Immunol. 2006 Apr;6(4):295-307 - PubMed
  131. Cancer Res. 2011 Apr 15;71(8):2892-900 - PubMed
  132. Oncogene. 2008 Oct 6;27(45):5886-93 - PubMed
  133. J Immunol Methods. 2011 Jun 30;369(1-2):59-68 - PubMed
  134. J Autoimmun. 2012 Dec;39(4):377-87 - PubMed
  135. Cell. 2012 Jul 6;150(1):29-38 - PubMed
  136. Clin Cancer Res. 2012 Jun 1;18(11):3022-9 - PubMed
  137. Cancer Res. 2012 Jul 15;72(14):3557-69 - PubMed
  138. Br J Dermatol. 2011 May;164(5):1052-60 - PubMed
  139. J Immunol. 1995 Aug 1;155(3):1151-64 - PubMed
  140. Annu Rev Immunol. 2004;22:329-60 - PubMed
  141. PLoS One. 2010 May 03;5(5):e10436 - PubMed
  142. Nat Commun. 2011 Dec 20;2:600 - PubMed
  143. J Immunol. 2007 Feb 15;178(4):2155-62 - PubMed
  144. Eur J Immunol. 2010 Apr;40(4):1099-106 - PubMed
  145. J Immunol. 2013 Apr 1;190(7):3235-45 - PubMed
  146. Cancer Res. 2009 May 15;69(10):4335-45 - PubMed
  147. Cancer Res. 2009 Oct 15;69(20):8085-93 - PubMed
  148. J Immunol. 2010 Apr 1;184(7):3433-41 - PubMed
  149. Carcinogenesis. 2013 Jun;34(6):1296-303 - PubMed
  150. J Immunol. 2002 Sep 1;169(5):2756-61 - PubMed
  151. Nature. 2007 Nov 22;450(7169):566-9 - PubMed
  152. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6430-5 - PubMed
  153. Blood. 2004 Mar 1;103(5):1755-62 - PubMed
  154. J Immunol. 2011 Apr 1;186(7):3918-26 - PubMed
  155. J Immunol. 2010 Jun 15;184(12):6709-18 - PubMed
  156. Cancer Res. 2008 Aug 1;68(15):6350-9 - PubMed
  157. J Immunol. 2010 Apr 1;184(7):3570-81 - PubMed
  158. Nat Med. 2011 Jul 24;17(8):975-82 - PubMed
  159. Eur J Immunol. 2009 Jun;39(6):1466-71 - PubMed
  160. J Exp Med. 2011 Aug 1;208(8):1571-7 - PubMed
  161. J Immunother. 2006 Jul-Aug;29(4):416-24 - PubMed
  162. J Immunother. 2009 Feb-Mar;32(2):101-8 - PubMed
  163. Cancer Immunol Immunother. 2011 Jul;60(7):909-18 - PubMed
  164. Ann Rheum Dis. 2013 Sep 1;72(9):1549-58 - PubMed
  165. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 - PubMed
  166. Immunity. 2009 Jun 19;30(6):899-911 - PubMed

Publication Types